× Industry Reports Services Press Release Contact us About us

Europe Antiviral Drugs Market Size By Age Group (Pediatric, Adult, Geriatric), By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors), By Indication (Influenza, HIV AIDS, Hepatitis, Herpes Simplex Virus [HSV], Coronavirus Infection), By Type (Branded, Generic), Research Report, Country Outlook (Germany, UK, France, Italy, Spain, Russia, Poland, Netherlands, Sweden, Switzerland), Price Trends, Growth Prospects, Competitive Industry Share & Forecasts, 2021 – 2027
Published Date: March 2021 | Publisher: Graphical Research Report ID: GR1737 | Delivery : PDF  Request Free Sample

Europe Antiviral Drugs Market size exceeded USD 8.5 million in 2020 and is projected to register a growth of over -1.9% from 2021 to 2027.

Anti-viral drugs are the medicines that can treat symptoms related to viral infections and diseases. These drugs are prescription medicine such as pills, liquid, an inhaled powder, and intravenous solution.
 

Europe Antiviral Drugs Market

Get more details on this report - Request Free Sample PDF

Incidence of COVID-19 has significantly increased the usage of anti-viral drugs. Growing number of drug approvals coupled with increasing drug production for COVID-19 treatment are the factors contributing to the market growth. The use of anti-viral drugs significantly decreases the viral load and infection. Anti-viral drugs, in the combination with isolation, contact tracing, and quarantine, resulted in significant decrease in the final size of peak incidence of infection.

Increasing marketing authorisation for COVID-19 prescription drugs will augment demand for the drugs in near future. For instance, in September 2020, Russia authorised the first COVID-19 drug, Coronavir for sale in pharmacies. Russia has approved the usage of drugs for patients with mild to moderate infections. For instance, in July 2020, European Commission signed a contract with Gilead to secure treatment of doses of Remdesivir.

European Market, By Drug Class

The reverse transcriptase inhibitors segment held more than 40% market share in 2020 due to wide usage of reverse transcriptase inhibitors in various applications. In addition, increasing use of reverse transcriptase inhibitors in HIV and increasing FDA approval of these drugs are the factors increasing the drug usage.

European Market, By Indication

The HIV AIDS segment dominated over 50% market share in 2020. Increasing cases of HIV AIDS coupled with growing use of anti-viral drugs in HIV treatment are the factors are contributing to the market size. According to the National AIDS Trust, in 2019, there were 105,200 people living with HIV in the UK.

European Market, By Type

The branded drugs observed high demand in 2020 owing to high cost of drugs. Branded drugs have original drug class that are developed and manufactured by original pharmaceutical company. Increasing research and development expenditure and rising demand for branded drugs for various infectious diseases due to greater specificity and efficacy are the factors stimulating the market revenue.

European Market, By Age Group

The geriatric segment accounted for high market revenue share in 2020 on account of rising incidence of various chronic and infectious disease. Growing baby boomer population coupled with high cost of treatment are the factors contributing to the growth of the market. According to the Eurostat, there were more than 20% of the EU-27 population, aged 65 years and over.

European Market, By Country

Germany antiviral drugs market size was more than USD 1 billion in 2020. Increasing use of anti-viral medicines for treatment of various infectious disease such as coronavirus and Hepatitis will boost the market demand. Moreover, rising geriatric population is prone to various chronic and infectious disease, thereby increasing the demand for anti-viral therapeutics. According to the American Association of Retired Persons stats, Germany is one of only five “Super-aged” societies in the world. The population of Germany aged 65 years and over is estimated to grow by 41% to 24 million by 2050.

Competitive Industry Landscape

Some of the established industry players are Gilead Science, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, AstraZeneca, and Abbvie. Market players are expediting research and development activities and speedy approval of anti-viral drugs in the region. For instance, in March 2020, scientists at German Primate Center- Leibniz Institute for Primary Research identified potential drug for COVID-19.
 

Frequently Asked Question(FAQ) :

The market for antiviral drugs in Europe surpassed USD 8.5 million in 2020 and will grow at a rate of -1.9% through 2027.
Germany market was valued at over USD 1 billion in 2020 and will expand on account of the surging deployment of antiviral drugs for the treatment of infectious diseases comprising hepatitis and coronavirus.
The HIV AIDS segment held more than 50% of the total market revenue in 2020 and will grow due to the rising cases of the disease.
The reverse transcriptase inhibitors segment accounted for more than 40% of the overall industry revenue in 2020 and will expand owing to the increasing FDA approvals for them in the treatment of HIV and across numerous applications.

Premium Report

Have questions?
  • Inquire Before Buying
  • Why Choose us?

    • on-time delivery On-Time Delivery

      We commit to on-time delivery of reports to keep you ahead.

    • assured quality Assured Quility

      With a wide network of industry experts and trained in-house analysts, we assure best service quality.

    • Custom Research Service

      We offer research services to meet specific client requirements and provide them with actionable insights on target markets.

    • payment security Payment Security

      Our safe payment gateway gives you full control of your personal data, at all times.

    Connect with our sales team

     1-800-986-6917

     [email protected]